Porcine xenoreactive glycan antigens (XA)

Porcine xenoreactive glycan antigens, primarily alpha-1,3-galactose (alpha-Gal), N-glycolylneuraminic acid (Neu5Gc), and the SDa blood group-like antigen, are the major carbohydrate barriers to successful xenotransplantation (Cooper et al., 2023). These antigens are expressed on the surface of porcine tissues, including the EGEN-2784 kidney cell line, and are recognized by pre-existing human natural antibodies (XNAs), mainly of the IgM class (Kim et al., 2023). This recognition triggers the classical complement pathway, leading to hyperacute rejection (HAR), a process characterized by rapid endothelial damage, thrombosis, and graft failure within minutes to hours (Nature, 2023). To mitigate this, advanced xenotransplantation platforms like EGEN-2784 utilize CRISPR/Cas9 to knock out the genes responsible for synthesizing these glycans, specifically GGTA1, CMAH, and B4GALNT2 (eGenesis, 2023). Pharmacological management of the recipient often involves complement inhibitors such as eculizumab and antibody-cleaving enzymes like imlifidase to prevent immune-mediated destruction of the graft (PubMed, 2023).

Other names

alpha-GalNeu5GcSDa antigenGalactose-alpha-1,3-galactoseN-glycolylneuraminic acidXenoreactive natural antibody targetsPorcine carbohydrate antigens

Inhibition of the complement cascade (e.g., C5 inhibition), enzymatic cleavage of xenoreactive IgG antibodies, or genetic ablation of glycan synthases (GGTA1, CMAH, B4GALNT2) to eliminate the target antigens from the donor organ.